Urethritis medical therapy: Difference between revisions

Jump to navigation Jump to search
m (Reverted edits by YazanDaaboul (talk) to last revision by Maliha Shakil)
No edit summary
Line 2: Line 2:
{{Urethritis}}
{{Urethritis}}


{{CMG}}; {{AE}}{{CZ}}{{SR}}
{{CMG}}; {{AE}}{{CZ}} {{SR}}


==Overview==
==Overview==
Antimicrobial therapy is indicated in urethritis.  Gonococcal urethritis is treated with [[Azithromycin]] with either [[Ceftriaxone]] or [[Cefixime]].  For patients with nongonococcal urethritis, the preferred regimen is either [[Azithromycin]] or [[Doxycycline]].  Patients with recurrent urethritis are treated with a combination of [[Metronidazole]] and either [[Tinidazole]] or [[Azithromycin]].
Empiric Antimicrobial therapy is indicated in urethritis.  Non-gonococcal urethritis is generally treated with either [[azithromycin]] or doxycyline.  For patients with gonococcal urethritis, the preferred regimen is either combination of [[ceftriaxone]] and [[azithromycin]].


==Medical Therapy==
==Medical Therapy==
Treatment should be initiated as soon as possible after diagnosis.
*All patients with urethritis should be treated empirically once the diagnosis is confirmed.
===Pharmacotherapy===
A variety of drugs may be prescribed based on the cause of the patient's urethritis.  Some examples of medications based on causes include:
 
*[[Clotrimazole]] (Mycelex) - Trichomonas
*[[Doxycycline]] (Vibramycin) - [[Chlamydia]]
*[[Fluconazole]] (Diflucan) - Monilial
*[[Metronidazole]] (Flagyl) - Trichomonas
*[[Nitrofurantoin]] - Bacterial Infection
*[[Nystatin]] (Mycostatin) - Monilial
*[[Co-trimoxazole]], which is a combination of Sulfamethoxazole and Trimethoprim in a ratio of 5 to 1 (Septrin, Bactrim) - Bacterial Infection


===Antimicrobial Therapy===
===Antimicrobial Therapy===
Line 27: Line 17:
:* Alternative regimen (3): [[Levofloxacin]] 500 mg PO qd for 7 days  
:* Alternative regimen (3): [[Levofloxacin]] 500 mg PO qd for 7 days  
:* Alternative regimen (4): [[Ofloxacin]] 300 mg PO bid for 7 days
:* Alternative regimen (4): [[Ofloxacin]] 300 mg PO bid for 7 days
 
:*Note: HIV-positive patients with non-gonococcal urethritis should receive the same treatment regimen as those who are HIV-negative
*2. '''Gonococcal Urethritis'''
*2. '''Gonococcal Urethritis'''
:* Preferred regimen: [[Ceftriaxone]] 250 mg IM in a single dose {{and}} [[Azithromycin]] 1 g PO in a single dose
:* Preferred regimen: [[Ceftriaxone]] 250 mg IM in a single dose {{and}} [[Azithromycin]] 1 g PO in a single dose
:* Alternative regimen: [[Cefixime]] 400 mg PO in a single dose {{and}} [[Azithromycin]] 1 g PO in a single dose (if ceftriaxone is not available)
:* Alternative regimen: [[Cefixime]] 400 mg PO in a single dose {{and}} [[Azithromycin]] 1 g PO in a single dose (if ceftriaxone is not available)
*3. '''Recurrent and Persistent Urethritis'''
*3. '''Recurrent and Persistent Urethritis'''
:* Preferred regimen: [[Metronidazole]] 2 g PO in a single dose {{or}} [[Tinidazole]] 2 g PO in a single dose {{and}} [[Azithromycin]] 1 g PO in a single dose for 7 days
:* Preferred regimen: ([[Metronidazole]] 2 g PO in a single dose {{or}} [[Tinidazole]] 2 g PO in a single dose) {{and}} [[Azithromycin]] 1 g PO in a single dose for 7 days
:* Alternative regimen, ''M. genitalium'': [[Moxifloxacin]] 400 mg PO qd for 7 days


===Follow-Up===
===Follow-Up===
*Patients should be instructed to return for evaluation if symptoms persist or recur after completion of therapy.
*Symptoms alone, without documentation of signs or laboratory evidence of urethral inflammation, are not a sufficient basis for re-treatment.
*Providers should be alert to the possibility of chronic prostatitis/chronic pelvic pain syndrome in male patients experiencing persistent pain (perineal, penile, or pelvic), discomfort, irritative voiding symptoms, pain during or after ejaculation, or new-onset premature ejaculation lasting for > 3 months.
*Unless a patient’s symptoms persist or therapeutic noncompliance or reinfection is suspected, a test-of-cure (i.e., repeat testing 3–4 weeks after completing therapy) is not recommended for persons with documented ''Chlamydia'' or gonococcal infections who have received treatment with recommended or alternative regimens. However, because men with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months after treatment, repeat testing for all men diagnosed with ''Chlamydia'' or ''Gonorrhea'' is recommended 3–6 months after treatment, regardless of whether patients believe that their sex partners were treated.
*In individuals who have persistent symptoms after treatment without signs and symptoms of urethritis, the efficacy of extended-duration antimicrobials has not been demonstrated. Individuals who have persistent or recurrent urethritis can be retreated with the initial regimen if they did not comply with the treatment regimen or if they were re-exposed to an untreated sex partner. Persistent urethritis after doxycycline treatment might be caused by doxycycline-resistant ''U. urealyticum'', ''M. genitalium'', or ''T. vaginalis''. 


Patients should be instructed to return for evaluation if symptoms persist or recur after completion of therapy. Symptoms alone, without documentation of signs or laboratory evidence of urethral inflammation, are not a sufficient basis for retreatment. Providers should be alert to the possibility of chronic prostatitis/chronic pelvic pain syndrome in male patients experiencing persistent pain (perineal, penile, or pelvic), discomfort, irritative voiding symptoms, pain during or after ejaculation, or new-onset premature ejaculation lasting for >3 months.
===Treatment of Sexual Partners===
 
*All sex partners within the preceding 60 days should be referred for evaluation, testing, and empiric treatment with a drug regimen effective against Chlamydia.
Unless a patient’s symptoms persist or therapeutic noncompliance or reinfection is suspected by the provider, a test-of-cure (i.e., repeat testing 3–4 weeks after completing therapy) is not recommended for persons with documented chlamydia or gonococcal infections who have received treatment with recommended or alterative regimens. However, because men with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months after treatment (251,252), repeat testing of all men diagnosed with chlamydia or gonorrhea is recommended 3–6 months after treatment, regardless of whether patients believe that their sex partners were treated (251).
*A specific diagnosis might facilitate partner referral. Therefore, testing for gonorrhea and chlamydia is encouraged. Because a substantial proportion of female partners of males with non-chlamydial, non-gonococcal urethritis are infected with ''Chlamydia'', partner treatment is recommended for males with non-gonococcal urethritis regardless of whether a specific etiology is identified.
 
===Partner Referral===
 
A specific diagnosis might facilitate partner referral. Therefore, testing for gonorrhea and chlamydia is encouraged. Because a substantial proportion of female partners of males with nonchlamydial NGU are infected with chlamydia, partner management is recommended for males with NGU regardless of whether a specific etiology is identified. All sex partners within the preceding 60 days should be referred for evaluation, testing, and empiric treatment with a drug regimen effective against chlamydia. Expedited partner treatment and patient referral are alternative approaches to treating partners (71).
 
===Recurrent Urethritis===
Objective signs of urethritis should be present before the initiation of antimicrobial therapy. In persons who have persistent symptoms after treatment without objective signs of urethritis, the value of extending the duration of antimicrobials has not been demonstrated. Persons who have persistent or recurrent urethritis can be retreated with the initial regimen if they did not comply with the treatment regimen or if they were reexposed to an untreated sex partner. Persistent urethritis after doxycycline treatment might be caused by doxycycline-resistant U. urealyticum orM. genitalium. T. vaginalis is also known to cause urethritis in men; a urethral swab, first void urine, or semen for culture or a NAAT (PCR or TMA) on a urethral swab or urine can be performed. If compliant with the initial regimen and re-exposure can be excluded, the following regimen is recommended while awaiting the results of the diagnostic tests.
 
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Recurrent Non-gonococal Urethritis }}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ Metronidazole]] 2 gm po single dose'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azithromycin]] 1 gm po x 1 dose'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Tinidazole]] 2 gm po x 1 dose'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azithromycin]] 1 gm po x 1 dose'''''
|-
|}
|}
 
Studies involving a limited number of patients who experienced NGU treatment failures have demonstrated that Moxifloxacin 400 mg orally once daily for 7 days is highly effective against M. genitalium (253,254). Men with a low probability of T. vaginalis (e.g., MSM) are unlikely to benefit from the addition of metronidazole or tinidazole.
 
Urologic examinations usually do not reveal a specific etiology for urethritis. A four-glass Meares-Stamey lower-urinary-tract localization procedure (or four-glass test) might be helpful in localizing pathogens to the prostate (255). A substantial proportion of men with chronic nonbacterial prostatitis/chronic pelvic pain syndrome have evidence of urethral inflammation without any identifiable microbial pathogens. Estimates vary considerably depending on the source and sensitivity of the assay, but one study demonstrated that in 50% of men with this syndrome, ≥5 WBCs per high-power field were detected in expressed prostatic secretions (256). Referral to a urologist should be considered for men who experience pain for more than 3 months within a 6-month period.
 
If men require treatment with a new antibiotic regimen for persistent urethritis and a sexually transmitted agent is the suspected cause, all partners in the past 60 days before the initial diagnosis and any interim partners should be referred for evaluation and appropriate treatment.
 
===Special Considerations===
 
'''HIV Infection'''
 
Gonococcal urethritis, chlamydial urethritis, and nongonococcal, nonchlamydial urethritis might facilitate HIV transmission. Patients who have NGU and also are infected with HIV should receive the same treatment regimen as those who are HIV negative.


==References==
==References==

Revision as of 15:54, 6 October 2015

Urinary Tract Infections Main Page

Sexually Transmitted Diseases Main Page

Urethritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Urethritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Urethritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Urethritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onUrethritis medical therapy

CDC onUrethritis medical therapy

Urethritis medical therapyin the news

Blogs onUrethritis medical therapy

Directions to Hospitals Treating Urethritis

Risk calculators and risk factors for Urethritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2] Sujit Routray, M.D. [3]

Overview

Empiric Antimicrobial therapy is indicated in urethritis. Non-gonococcal urethritis is generally treated with either azithromycin or doxycyline. For patients with gonococcal urethritis, the preferred regimen is either combination of ceftriaxone and azithromycin.

Medical Therapy

  • All patients with urethritis should be treated empirically once the diagnosis is confirmed.

Antimicrobial Therapy

  • 1. Nongonococcal Urethritis
  • Preferred regimen: Azithromycin 1 g PO in a single dose OR Doxycycline 100 mg PO bid for 7 days
  • Alternative regimen (1): Erythromycin base 500 mg PO qid for 7 days
  • Alternative regimen (2): Erythromycin ethylsuccinate 800 mg PO qid for 7 days
  • Alternative regimen (3): Levofloxacin 500 mg PO qd for 7 days
  • Alternative regimen (4): Ofloxacin 300 mg PO bid for 7 days
  • Note: HIV-positive patients with non-gonococcal urethritis should receive the same treatment regimen as those who are HIV-negative
  • 2. Gonococcal Urethritis
  • Preferred regimen: Ceftriaxone 250 mg IM in a single dose AND Azithromycin 1 g PO in a single dose
  • Alternative regimen: Cefixime 400 mg PO in a single dose AND Azithromycin 1 g PO in a single dose (if ceftriaxone is not available)
  • 3. Recurrent and Persistent Urethritis

Follow-Up

  • Patients should be instructed to return for evaluation if symptoms persist or recur after completion of therapy.
  • Symptoms alone, without documentation of signs or laboratory evidence of urethral inflammation, are not a sufficient basis for re-treatment.
  • Providers should be alert to the possibility of chronic prostatitis/chronic pelvic pain syndrome in male patients experiencing persistent pain (perineal, penile, or pelvic), discomfort, irritative voiding symptoms, pain during or after ejaculation, or new-onset premature ejaculation lasting for > 3 months.
  • Unless a patient’s symptoms persist or therapeutic noncompliance or reinfection is suspected, a test-of-cure (i.e., repeat testing 3–4 weeks after completing therapy) is not recommended for persons with documented Chlamydia or gonococcal infections who have received treatment with recommended or alternative regimens. However, because men with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months after treatment, repeat testing for all men diagnosed with Chlamydia or Gonorrhea is recommended 3–6 months after treatment, regardless of whether patients believe that their sex partners were treated.
  • In individuals who have persistent symptoms after treatment without signs and symptoms of urethritis, the efficacy of extended-duration antimicrobials has not been demonstrated. Individuals who have persistent or recurrent urethritis can be retreated with the initial regimen if they did not comply with the treatment regimen or if they were re-exposed to an untreated sex partner. Persistent urethritis after doxycycline treatment might be caused by doxycycline-resistant U. urealyticum, M. genitalium, or T. vaginalis.

Treatment of Sexual Partners

  • All sex partners within the preceding 60 days should be referred for evaluation, testing, and empiric treatment with a drug regimen effective against Chlamydia.
  • A specific diagnosis might facilitate partner referral. Therefore, testing for gonorrhea and chlamydia is encouraged. Because a substantial proportion of female partners of males with non-chlamydial, non-gonococcal urethritis are infected with Chlamydia, partner treatment is recommended for males with non-gonococcal urethritis regardless of whether a specific etiology is identified.

References

Template:WH Template:WS